Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer

NCT05318469 is registered in ClinicalTrials.gov with Yuan Yuan as lead sponsor.

NCT NCT05318469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05318469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer
Lead sponsor
Yuan Yuan
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 13, 2023
Completion date
October 31, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic triple-negative breast carcinoma